What is the recommended method to switch from Lexapro (escitalopram) to mirtazapine, including tapering schedule and initial dosing?

Switching from Lexapro (Escitalopram) to Mirtazapine

Gradually taper escitalopram over 1–2 weeks using a hyperbolic reduction schedule, then initiate mirtazapine at 15 mg once daily after completing the taper or during the final days when escitalopram is at a very low dose.

Tapering Escitalopram

• Use a hyperbolic (exponential) taper by reducing the current dose by 10% of the current dose every 2–4 weeks (e.g., 20 mg → 18 mg → 16.2 mg → 14.6 mg, continuing this pattern). 1

• When the dose becomes low (below 10 mg), slow the taper further to 5% or smaller decrements to avoid abrupt receptor-occupancy drops that trigger withdrawal symptoms. 1

• Continue tapering to doses well below the minimum therapeutic level (far under 10 mg) before complete cessation—do not stop at 10 mg and then discontinue abruptly. 1

• A practical alternative for a faster switch: reduce from full dose to 75% for 3–4 days, then to 50% for 3–4 days, then to 25% for 3–4 days before stopping, though this carries higher withdrawal risk than hyperbolic tapering. 2

• Never use alternate-day dosing or skip doses during tapering, as fluctuating drug levels create severe receptor occupancy variation and markedly increase withdrawal risk. 1, 3

Initiating Mirtazapine

• Start mirtazapine at 15 mg once daily, preferably in the evening prior to sleep, after the escitalopram taper is completed or during the final 2–3 days when escitalopram is at a very low dose. 4, 2

• Dose changes should not be made in intervals of less than 1–2 weeks to allow sufficient time for evaluation of response. 4

• If inadequate response occurs, increase mirtazapine up to a maximum of 45 mg per day. 4

Monitoring for Withdrawal (Discontinuation) Syndrome

• Monitor patients closely during the first 1–2 weeks after each dose reduction to detect emergent withdrawal symptoms. 1

• Common escitalopram withdrawal symptoms include dizziness, fatigue, nausea, insomnia, sensory disturbances (paresthesias, "electric shock" sensations), anxiety, irritability, agitation, gastrointestinal upset, and balance problems. 2, 1

• If withdrawal symptoms are intolerable, resume the most recent tolerated dose and then decrease more gradually, extending the interval between reductions to 3–4 weeks or longer. 1

• Distinguish withdrawal from relapse: withdrawal has sudden onset after a dose change, whereas true relapse develops gradually over time. 1

Monitoring for Serotonin Syndrome

• Although the risk is lower when switching between antidepressants sequentially (rather than combining them), early monitoring during the first 24–48 hours after initiating mirtazapine is essential. 2

• Watch for serotonin syndrome symptoms: mental status changes (agitation, confusion), neuromuscular hyperactivity (tremor, hyperreflexia, rigidity), and autonomic hyperactivity (tachycardia, hypertension, diaphoresis). 2

• If serotonin syndrome is identified, stop all serotonergic agents immediately and provide supportive care. 2

Rationale for Switching Strategy

• Switching from one antidepressant to another is appropriate when there is inadequate response after 6–8 weeks of initial treatment, though early switching at 2–4 weeks is possible in cases of clear non-response. 5, 6

• Moderate-quality evidence shows no difference in response rates when switching from an SSRI to various second-generation antidepressants, including mirtazapine. 7, 5

• Two trials (1,231 participants) found no differences in efficacy and safety between switching from an SSRI to mirtazapine versus augmenting the SSRI with mirtazapine, supporting either strategy. 7

• Direct switching is possible and well tolerated in most instances except when MAOIs or tricyclic antidepressants are involved, making the escitalopram-to-mirtazapine switch straightforward. 6

Special Considerations

• Screen patients for bipolar disorder, mania, or hypomania before initiating mirtazapine, as antidepressants can trigger manic episodes in susceptible individuals. 4

• Mirtazapine is particularly effective for improving sleep, appetite, and weight in MDD patients, while escitalopram is more effective for daily activity and concentration difficulties. 8

• Increase patient contact frequency (weekly or more) during the switch to promptly identify adverse events or worsening depression. 2

• Advise patients to report severe agitation, confusion, rapid heart rate, muscle rigidity, fever, or suicidal thoughts promptly, as these may indicate serious complications. 1

Key Pitfalls to Avoid

• Do not abruptly discontinue escitalopram—gradual tapering reduces withdrawal syndrome risk from up to 44% with abrupt cessation to much lower rates. 1, 9

• Do not combine escitalopram with MAOIs—at least 14 days must elapse between stopping escitalopram and starting an MAOI, or vice versa. 9, 4

• Do not use benzodiazepines routinely to manage withdrawal symptoms, as they introduce additional withdrawal risks. 1